OTLK
Price:
$2.27
Market Cap:
$97.28M
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, In...[Read more]
Industry
Biotechnology
IPO Date
2016-06-14
Stock Exchange
NASDAQ
Ticker
OTLK
According to Outlook Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -35.27%. This represents a change of -397.78% compared to the average of 11.85% of the last 4 quarters.
The mean historical ROE of Outlook Therapeutics, Inc. over the last ten years is -82.74%. The current -35.27% ROE has changed -57.37% with respect to the historical average. Over the past ten years (40 quarters), OTLK's ROE was at its highest in in the June 2023 quarter at 375.70%. The ROE was at its lowest in in the June 2016 quarter at -1428.35%.
Average
-82.74%
Median
135.52%
Minimum
-1246.96%
Maximum
1.03%
Discovering the peaks and valleys of Outlook Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 409.30%
Maximum Annual ROE = 1.03%
Minimum Annual Increase = -489.00%
Minimum Annual ROE = -1246.96%
Year | ROE | Change |
---|---|---|
2024 | 103.13% | -74.75% |
2023 | 408.53% | -154.04% |
2022 | -756.04% | -34.48% |
2021 | -1153.96% | -7.46% |
2020 | -1246.96% | -489.00% |
2019 | 320.56% | 121.69% |
2018 | 144.60% | 14.37% |
2017 | 126.43% | -87.66% |
2016 | 1.03% | 409.30% |
2015 | 201.26% | 319.19% |
The current ROE of Outlook Therapeutics, Inc. (OTLK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-81.46%
5-year avg
-529.06%
10-year avg
-82.74%
Outlook Therapeutics, Inc.’s ROE is greater than Fortress Biotech, Inc. (-195.97%), less than Eyenovia, Inc. (789.91%), greater than Opus Genetics, Inc. (-270.35%), less than Galera Therapeutics, Inc. (11.31%), greater than Citius Pharmaceuticals, Inc. (-60.52%), greater than VistaGen Therapeutics, Inc. (-58.88%), less than Iterum Therapeutics plc (310.64%), less than Guardion Health Sciences, Inc. (71.14%), greater than vTv Therapeutics Inc. (-144.87%),
Company | ROE | Market cap |
---|---|---|
-195.97% | $57.37M | |
789.91% | $80.75M | |
-270.35% | $65.63M | |
11.31% | $1.96M | |
-60.52% | $18.21M | |
-58.88% | $65.60M | |
310.64% | $39.20M | |
71.14% | $4.35M | |
-144.87% | $44.18M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Outlook Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Outlook Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Outlook Therapeutics, Inc.'s ROE?
How is the ROE calculated for Outlook Therapeutics, Inc. (OTLK)?
What is the highest ROE for Outlook Therapeutics, Inc. (OTLK)?
What is the 3-year average ROE for Outlook Therapeutics, Inc. (OTLK)?
What is the 5-year average ROE for Outlook Therapeutics, Inc. (OTLK)?
How does the current ROE for Outlook Therapeutics, Inc. (OTLK) compare to its historical average?